[Pubmed] Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohor

[RSS-Bot]

J Neurol. 2022 Aug 22. doi: 10.1007/s00415-022-11345-y. Online ahead of print.

ABSTRACT

INTRODUCTION: To describe the efficacy of subcutaneous immunoglobulin (SCIg) in patients with myasthenia gravis (MG).

METHODS: This was a retrospective study conducted in the neuromuscular referral center of Bordeaux (between January 1, 2014 and March 31, 2021) with MG patients treated with SCIg. The main outcome was SCIg efficacy assessed by the before and after SCIg Myasthenia Gravis Foundation of America (MGFA) clinical classification, the duration of hospitalization and the number of days of orotracheal intubation (OTI).

RESULTS: Sixteen patients were included in the study (11 females; 5 males). Nine patients were still treated with SCIg at the end of the study (March 31, 2021) and then underwent prospective follow-up. The average age of the patients was 56.1 (19-83) years. The median duration of MG at onset of SCIg was 37.4 months. Eight patients (50%) remained stable (4 in stage MGFA-IV and 4 in MGFA-III). Eight patients (50%) improved: 3 from MGFA-IV to MGFA-III, 1 from MGFA-IV to MGFA-II, 1 from MGFA-IV to MGFA-I, 2 from MGFA-III to MGFA-II and 1 from MGFA-III to MGFA-I (no patient worsened). The duration of disease progression did not appear to affect the response to SCIg therapy. The number of hospital days per month was significantly reduced after SCIg compared to before, and the number of days in intensive care unit and the number of days of OTI were also reduced. Only minor adverse effects were noted, and 80% of patients were in favor of continuing SCIg.

CONCLUSIONS: SCIg is a well-tolerated and useful treatment in MG, offering interesting perspectives in the management of MG patients. However, further large-scale prospective studies are needed to confirm these results.

PMID:35995991 | DOI:10.1007/s00415-022-11345-y


Source: https://pubmed.ncbi.nlm.nih.gov/3599599 ... 6&v=2.17.7